Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Fry, James A
EBS-101-TD-391, NCT06021522: A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder	Recruiting	3	150	Europe, Canada, US, RoW	Ecopipam, Ecopipam Hydrochloride	Emalex Biosciences Inc.	Tourette Syndrome	11/24	03/27
D1AMOND, NCT05615220: Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults	Recruiting	3	196	Europe, Canada, US, RoW	Ecopipam Hydrochloride	Emalex Biosciences Inc.	Tourette Disorder	12/24	12/24
Kolaski, Diane
C4951003, NCT04743141: Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine	Recruiting	3	200	Europe, US	Rimegepant (PF-07899801)	Pfizer	Acute Treatment of Migraine	06/27	06/27
NCT04649242 / 2020-003517-35: Randomized Study in Children and Adolescents With Migraine: Acute Treatment	Recruiting	3	2100	Europe, Canada, Japan, US, RoW	Rimegepant/BHV3000, Matching placebo	Pfizer	Pediatric Migraine	01/29	01/29